Inter Collegas, Год журнала: 2024, Номер 11(4)
Опубликована: Дек. 31, 2024
Background. The unprecedented in the history of mankind problem COronaVIrus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2), having raised a huge number fundamental questions about pathogenesis pneumonia. Aim. To analyse features community-acquired pneumonia COVID-19, markers inflammation, impact comorbidities, and implications for improving diagnosis treatment patients with comorbidities according to professional literature. Materials Methods. We analyzed literature on associated COVID-19 comorbid conditions. search scientific information was carried out using databases Scopus, Pub Med, Web Science, Google Scholar. Results. analysis showed that requires use modern polymerase chain reaction platforms verify SARS-CoV-2 virus, atypical bacterial pathogens, fungal flora determine drug resistance. is characterized development radiological patterns can only be detected Computed Tomography (CT) chest. Digital software processing CT images allows dynamics stage assess effectiveness presence residual changes. Community-acquired provokes hypercoagulability, but likelihood developing thrombosis much higher, which additional research medical correction. Conclusions. role outpatient care important increasing patient adherence timely diagnosis, prevention chronic diseases, contribute benign course reduces risk death. Keywords: inflammatory markers, thrombosis, coronavirus disease.
Язык: Английский